Rankings · Price against the business
Most free cash flow per dollar of price
Graded A or B, ranked by free cash flow over the last twelve months divided by market value. Banks and insurers are left out, and yields above 50% are treated as data problems rather than bargains.
152 companies meet this test
Figures as of September 30, 2026
| # | Company | Grade | Free cash flow yield | P/E | Revenue growth | Market value |
|---|---|---|---|---|---|---|
| 1 | AMNAMN HEALTHCARE SERVICES, INC. | B | 32.5% | 12.99 | -8% a year | $1.4B |
| 2 | ARDTArdent Health, Inc. | A | 20.4% | 19.29 | +8% a year | $1.5B |
| 3 | NUTXNUTEX HEALTH INC. | B+ | 19.1% | 8.31 | — | $1.4B |
| 4 | TAKTakeda Pharmaceutical Company Limited | B | 18.6% | 43.22 | +4% a year | $29.7B |
| 5 | GRFSGrifols SA | A | 17.9% | 27.90 | +7% a year | $5B |
| 6 | GDRXGoodRx Holdings, Inc. | B | 17.7% | 80.75 | +2% a year | $1.1B |
| 7 | BCRXBIOCRYST PHARMACEUTICALS, INC. | A | 17.7% | — | +45% a year | $2.1B |
| 8 | PCRXPACIRA BIOSCIENCES, INC. | A | 17.5% | 73.34 | +4% a year | $1B |
| 9 | SNYSanofi | B | 16.5% | 8.89 | +2% a year | $49.7B |
| 10 | HRMYHARMONY BIOSCIENCES HOLDINGS, INC. | A+ | 15.2% | 12.71 | +24% a year | $2.3B |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.